Name: Dulaglutide
Brand: Trulicity
Availability: InStock

Question 1

How does dulaglutide work to lower blood sugar?

Accepted Answer

Dulaglutide works by mimicking the natural incretin hormone GLP-1. When blood glucose is elevated, it binds to GLP-1 receptors on pancreatic beta cells to stimulate insulin release. It simultaneously suppresses inappropriate glucagon secretion from alpha cells (which would otherwise raise blood sugar), moderately slows gastric emptying to reduce postprandial glucose spikes, and acts on the brain to reduce appetite. Importantly, its insulin-stimulating effect is glucose-dependent — it primarily works when blood sugar is high — which minimizes the risk of hypoglycemia compared to sulfonylureas or exogenous insulin alone.

Question 2

What makes dulaglutide convenient as a once-weekly injection?

Accepted Answer

Dulaglutide's once-weekly dosing is made possible by its unique fusion protein design. The GLP-1 analog is covalently attached to a modified human IgG4 Fc antibody fragment, creating a large molecule (approximately 59.7 kDa) that is recycled by the neonatal Fc receptor (FcRn) in endothelial cells rather than being rapidly cleared by the kidneys. This extends its plasma half-life to approximately 5 days, allowing effective GLP-1 receptor activation throughout the entire week. The prefilled, single-dose pen device (Trulicity) features a hidden, pre-attached needle that automatically delivers the dose with the press of a button, further improving ease of use and adherence.

Question 3

What did the REWIND cardiovascular outcomes trial demonstrate?

Accepted Answer

The REWIND trial was a landmark study that enrolled 9,901 patients with type 2 diabetes — the majority (69%) without established cardiovascular disease — and followed them for a median of 5.4 years, the longest follow-up of any GLP-1 RA cardiovascular outcomes trial at the time. Dulaglutide 1.5 mg once weekly demonstrated a statistically significant 12% reduction in the primary composite outcome of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) with a hazard ratio of 0.88 (p=0.026). Importantly, the benefit was consistent across subgroups including those with and without prior cardiovascular disease, suggesting that dulaglutide provides cardiovascular protection broadly, not just in secondary prevention.

Question 4

How does dulaglutide compare with semaglutide?

Accepted Answer

Both dulaglutide and semaglutide are once-weekly GLP-1 receptor agonists approved for type 2 diabetes. In head-to-head comparison (SUSTAIN 7 trial), semaglutide 0.5 mg and 1.0 mg achieved greater HbA1c and weight reductions compared to dulaglutide 0.75 mg and 1.5 mg, respectively. However, dulaglutide offers certain practical advantages: its auto-injector pen is widely considered more user-friendly with a hidden needle, and it has extensive long-term cardiovascular data from the REWIND trial. The higher dulaglutide doses (3.0 mg and 4.5 mg, approved in 2020) narrow the efficacy gap. Choice between them often depends on individual patient factors, insurance coverage, device preference, and treatment goals.

Question 5

What was the AWARD clinical trial program?

Accepted Answer

The AWARD (Assessment of Weekly AdministRation of LY2189265 in Diabetes) program was a comprehensive Phase III clinical development program comprising 11 major trials (AWARD-1 through AWARD-11) that evaluated dulaglutide across virtually every clinically relevant type 2 diabetes treatment scenario. These trials studied dulaglutide as monotherapy, in combination with metformin, sulfonylureas, thiazolidinediones, SGLT2 inhibitors, and insulin, and compared it head-to-head against metformin, sitagliptin, exenatide BID, insulin glargine, and lispro. The program consistently demonstrated HbA1c reductions of 0.7–1.9% across doses, with dulaglutide showing superiority or non-inferiority to every active comparator studied.

Question 6

How should dulaglutide dose escalation be approached?

Accepted Answer

Dulaglutide treatment typically begins at 0.75 mg once weekly. If additional glycemic control is needed after at least 4 weeks, the dose can be increased to 1.5 mg once weekly. The newer higher doses — 3.0 mg and 4.5 mg — are available for patients requiring further intensification, with each step-up separated by at least 4 weeks to allow the body to adjust and minimize gastrointestinal side effects. The gradual dose escalation strategy is important for tolerability: starting at the lowest effective dose and increasing incrementally allows the gastrointestinal tract to adapt, reducing the incidence and severity of nausea, which is the most common side effect.

Question 7

How does the GLP-1-Fc fusion protein technology work in dulaglutide?

Accepted Answer

Dulaglutide employs a sophisticated fusion protein approach where two modified GLP-1 analog peptides are each covalently linked to a modified human IgG4 Fc fragment via a peptide linker, forming a homodimer. The IgG4 Fc fragment was chosen because it has minimal effector function (avoiding unwanted immune activation) while retaining the ability to bind the neonatal Fc receptor (FcRn). FcRn binding enables 'antibody recycling' — when dulaglutide is internalized by endothelial cells, the Fc fragment binds FcRn in the acidic endosome, redirecting the molecule back to the cell surface and into circulation rather than to lysosomal degradation. This recycling mechanism dramatically extends the molecule's half-life from minutes (native GLP-1) to approximately 5 days.

Question 8

What weight loss effects can be expected with dulaglutide?

Accepted Answer

In clinical trials, dulaglutide produced clinically meaningful weight reductions. At the 1.5 mg dose, typical weight loss ranged from 2–3 kg in the AWARD program. The higher doses showed progressively greater weight loss: AWARD-11 demonstrated weight reductions of -3.1 kg (1.5 mg), -4.0 kg (3.0 mg), and -4.7 kg (4.5 mg) over 36 weeks. While these weight effects are less than what is achieved with higher-dose semaglutide (2.4 mg), they are clinically relevant and contribute to improved insulin sensitivity, blood pressure, and lipid profiles. Weight loss with dulaglutide is mediated primarily through reduced appetite and caloric intake via central GLP-1 receptor activation in the hypothalamus.

Question 9

What are the concerns regarding pancreatitis and thyroid cancer with dulaglutide?

Accepted Answer

Like all GLP-1 receptor agonists, dulaglutide carries a boxed warning regarding thyroid C-cell tumors based on rodent studies showing that GLP-1 RAs cause dose-dependent thyroid C-cell hyperplasia and medullary thyroid carcinoma (MTC) in rats and mice. However, the relevance to humans is uncertain, as human thyroid C-cells express far fewer GLP-1 receptors than rodent C-cells. Dulaglutide is contraindicated in patients with personal or family history of MTC or Multiple Endocrine Neoplasia type 2 (MEN2). Regarding pancreatitis, cases of acute pancreatitis have been reported post-marketing, though the REWIND trial found no statistically significant increased risk. Patients should be advised to report symptoms of severe abdominal pain, and dulaglutide should be discontinued if pancreatitis is confirmed.

Question 10

Can dulaglutide be used together with insulin?

Accepted Answer

Yes, dulaglutide is approved for use in combination with insulin and has been specifically studied in this context. The AWARD-4 trial demonstrated that dulaglutide combined with prandial insulin lispro was superior to insulin glargine with insulin lispro for HbA1c reduction, with the added benefits of weight loss (versus weight gain with insulin glargine) and less hypoglycemia. Dulaglutide can be added to basal insulin (such as insulin glargine or detemir) to improve glycemic control without the need for multiple daily insulin injections. When combining with insulin, dose adjustments to the insulin may be needed to reduce hypoglycemia risk, and the two medications should be injected separately (not mixed).

Origin / Manufacturer	Recombinant fusion protein (GLP-1 analog-IgG4 Fc; produced in mammalian cell culture)
Regulatory Status	FDA-Approved (2014; CV indication 2020)EMA-Approved (2014)cGMP Manufactured
Active Components	DulaglutideSodium citrate dihydrateCitric acid anhydrousMannitolPolysorbate 80Water for injection
Storage	Store at 2–8°C (36–46°F) in original carton to protect from light. May be stored at room temperature (up to 30°C / 86°F) for up to 14 days. Do not freeze. Do not use if it has been frozen.
Shelf Life	24 months refrigerated in original packaging; 14 days at room temperature
Form Factor	Subcutaneous injection, single-dose prefilled pen (0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3.0 mg/0.5 mL, 4.5 mg/0.5 mL)

Dulaglutide

Specifications

Clinical Evidence

Frequently Asked Questions

Sources & References

Related Peptides

Exenatide

Liraglutide

Lixisenatide

Semaglutide